Export

You can select particular sections to be included in the output file.

Model List of Essential Medicines

Found 1190 recommendations for 591 medicines and 124 therapeutic equivalents
Removed recommendations and rejected applications are shown. Hide them.
  1. Abacavir General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Solid: 300 mg tablet (as sulfate)
  2. Abacavir + lamivudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)
  3. Abacavir + lamivudine + lopinavir + ritonavir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules
  4. Abemaciclib General information
    Section
    Targeted therapies
    Indications
  5. Abiraterone General information
    Section
    Hormones and antihormones
    • Oral > Solid: 250 mg; 500 mg
  6. Acetazolamide General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Oral > Solid: 250 mg
  7. Acetic acid General information
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 2% in alcohol
  8. Acetylcysteine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 200 mg per mL in 10 mL ampoule
    • Oral > Liquid: 10%; 20%
  9. Acetylsalicylic acid General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 300 to 500 mg
    Indications
    Section
    Anti-platelet medicines
    • Oral > Solid: 100 mg
    Section
    Juvenile joint diseases
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 50 to 150 mg
    Indications
  10. Aciclovir General information
    Section
    Antiherpes medicines
    • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg tablet
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 3% w/w
  11. Aclidinium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
  12. Activated charcoal General information
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Other: powder
  13. Adalimumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL
  14. Afatinib General information
    Section
    Targeted therapies
  15. Albendazole General information
    Section
    Antifilarials
    • Oral > Solid: 400 mg tablet (chewable)
    Indications
    Section
    Intestinal anthelminthics
    • Oral > Solid: 400 mg tablet (chewable)
    Section
    Cysticidal medicines
    • Oral > Solid: 400 mg tablet (chewable)
  16. Alcohol based hand rub General information
    Section
    Disinfectants
    • Local > Topical > Solution: 80% v/v ethanol; 75% v/v isopropyl alcohol
  17. Alcuronium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 5 mg per mL in 2 mL ampoule (alcuronium chloride)
    Indications
  18. All-trans retinoic acid General information
    Section
    Targeted therapies
    • Oral > Solid: 10 mg capsule
  19. Allopurinol General information
    Section
    Medicines used to treat gout
    • Oral > Solid: 100 mg
    Indications
    Section
    Supportive medicines
    • Oral > Solid: 100 mg; 300 mg
  20. Alteplase General information
    Section
    Thrombolytic medicines
    • Parenteral > General injections > IV: 10 mg in vial powder for injection; 20 mg in vial powder for injection; 50 mg in vial powder for injection
  21. Amidotrizoate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 420 mg iodine per mL in 20 mL ampoule (as sodium or meglumine salt)
    Indications
  22. Amikacin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 250 mg per mL in 2 mL vial (as sulfate)
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
    Section
    Antituberculosis medicines
    • Parenteral > General injections > unspecified: 100 mg per 2 mL in 2 mL vial (as sulfate); 250 mg per mL in 2 mL vial (as sulfate)
  23. Amiloride General information
    Section
    Diuretics
    • Oral > Solid: 5 mg (hydrochloride)
  24. Amiodarone General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 50 mg per mL in 3 ampoule (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 200 mg (hydrochloride); 400 mg (hydrochloride)
  25. Amitriptyline General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 25 mg; 10 mg; 75 mg
    Indications
    Section
    Medicines used in depressive disorders
    • Oral > Solid: 25 mg; 75 mg
  26. Amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 5 mg (as maleate, mesylate or besylate)
  27. Amodiaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 153 mg (as hydrochloride); 200 mg (as hydrochloride)
  28. Amodiaquine + sulfadoxine + pyrimethamine General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 76.5 mg (as hydrochloride) [3] + 250 mg + 12.5 mg [1] dispersible tablets in co-package; 153 mg (as hydrochloride) [3] + 500 mg + 25 mg [1] dispersible tablets in co-package
    Indications
  29. Amoxicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as trihydrate) powder for oral liquid; 250 mg per 5 mL (as trihydrate) powder for oral liquid
    • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate)
    • Parenteral > General injections > unspecified: 250 mg in vial (as sodium) powder for injection; 500 mg in vial (as sodium) powder for injection; 1 g in vial (as sodium) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule or tablet; 500 mg (anhydrous) capsule or tablet
    • Oral > Solid: 250 mg (as trihydrate); 500 mg (as trihydrate); 1 g (as trihydrate)
  30. Amoxicillin + clavulanic acid General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection; 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
    • Oral > Liquid: 125 mg + 31.25 mg powder for oral liquid; 250 mg + 62.5 mg powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
    • Oral > Liquid: 250 mg + 62.5 mg per 5 mL powder for oral liquid; 125 mg + 31.25 mg per 5 mL powder for oral liquid
    • Oral > Solid: 500 mg + 125 mg tablet
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)
    Section
    Antituberculosis medicines
    • Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as trihydrate) + 125 mg (as potassium salt)
  31. Amphotericin B General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IV: 50 mg powder for injection in vial (as deoxycholate or liposomal complex)
  32. Ampicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection; 1 g in vial (as sodium salt) powder for injection
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral suspension
    • Oral > Solid: 250 mg (anhydrous); 500 mg (anhydrous)
  33. Anakinra General information
    Section
    Juvenile joint diseases
    • Parenteral > General injections > SC: 100 mg per 0.67 mL in pre-filled syringe
  34. Anastrozole General information
    Section
    Hormones and antihormones
    • Oral > Solid: 1 mg tablet
  35. Anidulafungin General information
    Section
    Antifungal medicines
    Indications
  36. Anti-d immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 250 µg in single-dose vial
    • Parenteral > General injections > IM: 250 µg in single-dose vial
  37. Anti-rabies immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 150 IU per mL in vial
    • Parenteral > Locoregional injections > Other: 150 IU per mL in vial
    Indications
  38. Anti-rabies virus monoclonal antibodies General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 40 IU per mL in 1.25 mL vial (human); 40 IU per mL in 2.5 mL vial (human); 100 IU per mL in 2.5 mL vial (human); 300 IU per mL in 10 mL vial (murine); 600 IU per mL in 1 mL vial (murine); 600 IU per mL in 2.5 mL vial (murine); 600 IU per mL in 5 mL vial (murine)
    Indications
  39. Anti-tetanus immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IM: 500 IU in vial
    Indications
  40. Antirabies hyperimmune serum General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > unspecified: 1000 IU in 5 mL ampoule
    Indications
  41. Antivenom immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
  42. Antivenom sera General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IV:
  43. Apixaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  44. Aprepitant General information
    Section
    Antiemetic medicines
    • Oral > Liquid: 125 mg powder for oral suspension (in sachet)
    • Oral > Solid: 80 mg; 125 mg; 165 mg
  45. Arsenic trioxide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion
  46. Artemether General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 80 mg per mL in 1 mL ampoule (oily injection)
  47. Artemether + lumefantrine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 20 mg + 120 mg tablet; 20 mg + 120 mg dispersible tablet
  48. Artesunate General information
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 60 mg in ampoule containing anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution
    • Oral > Solid: 50 mg tablet
    • Local > Rectal > Other: 50 mg capsules; 200 mg capsules; 100 mg capsules
  49. Artesunate + amodiaquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 67.5 mg tablet; 50 mg + 135 mg tablet; 100 mg + 270 mg tablet
  50. Artesunate + mefloquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 25 mg + 55 mg tablet; 100 mg + 220 mg tablet
  51. Artesunate + pyronaridine tetraphosphate General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 60 mg + 180 mg tablet; 20 mg + 60 mg granules
  52. Ascorbic acid General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
  53. Asparaginase General information
    Section
    Cytotoxic medicines
    • Powder for injection: 10 000 IU in vial.
    • Parenteral > General injections > unspecified: 10000 IU in vial powder for injection
  54. Atazanavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)
  55. Atazanavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)
  56. Atenolol General information
    Section
    Antianginal medicines
    • Oral > Solid: 50 mg; 100 mg
    Indications
    Section
    Antihypertensive medicines
    • Oral > Solid: 50 mg; 100 mg
    Indications
  57. Atezolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
  58. Atorvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  59. Atracurium General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 10 mg per mL (besylate)
    Indications
  60. Atropine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (atropine sulfate)
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide for Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 0.1% (sulfate); 0.5% (sulfate); 1% (sulfate)
    Indications
  61. Azacitidine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
  62. Azathioprine General information
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 50 mg
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 100 mg in vial powder for injection (as sodium salt)
    • Oral > Solid: 50 mg
  63. Azithromycin General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 200 mg per 5 mL oral liquid
    • Oral > Solid: 250 mg (anhydrous) capsule; 500 mg (anhydrous) capsule
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 1.5% eye drops
    Indications
  64. Aztreonam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial powder for injection; 2 g in vial powder for injection
  65. Barium sulfate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Oral > Liquid: Aqueous suspension
  66. Bcg vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  67. Beclometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 50 µg per dose (dipropionate); 250 µg per dose (dipropionatae)
    Indications
    Therapeutic equivalent to budesonide for Asthma Asthma
  68. Beclometasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  69. Bedaquiline General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg tablet; 20 mg tablet
  70. Bendamustine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL
  71. Benzathine benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IM: 900 mg in vial benzylpenicillin powder for injection (= 1.2 million IU); 1.44 g in vial benzylpenicillin powder for injection (= 2.4 million IU)
  72. Benznidazole General information
    Section
    American trypanosomiasis
    • Oral > Solid: 100 mg tablet; 50 mg tablet (scored); 12.5 mg tablet
    Indications
  73. Benzoic acid + salicylic acid General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Cream: 6% + 3%
    • Local > Topical > Ointment: 6% + 3%
  74. Benzoyl peroxide General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 5%
    • Local > Topical > Lotion: 5%
    Indications
  75. Benzyl benzoate General information
    Section
    Dermatological medicines (topical) > Scabicides and pediculicides
    • Local > Topical > Lotion: 25%
  76. Benzylpenicillin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (=1 million IU as sodium or potassium salt); 3 g in vial powder for injection (=5 million IU as sodium or potassium salt)
    • Parenteral > General injections > unspecified: 600 mg in vial powder for injection (= 1 million IU as sodium or potassium salt); 3 g in vial powder for injection (= 5 million IU as sodium or potassium salt)
  77. Betamethasone General information
    Section
    Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 0.1% (as valerate)
    • Local > Topical > Ointment: 0.1% (as valerate)
  78. Bevacizumab General information
    Section
    Ophthalmological preparations > Anti-vascular endothelial growth factor (VEGF) preparations
    • Parenteral > Locoregional injections > Intravitreal: 25 mg per mL
  79. Bicalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 50 mg
  80. Binimetinib General information
    Section
    Targeted therapies
    Indications
  81. Biperiden General information
    Section
    Antiparkinsonism medicines
    • Parenteral > General injections > IV: 5 mg per mL in 1 mL ampoule (lactate)
    • Oral > Solid: 2 mg tablet (hydrochloride)
  82. Bisacodyl General information
    Section
    Laxatives
    Indications
    Therapeutic equivalent to senna for Constipation
  83. Bisoprolol General information
    Section
    Antianginal medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Section
    Medicines used in heart failure
    • Oral > Solid: 1.25 mg; 5 mg
    Indications
    Section
    Antiarrhythmic medicines
    • Oral > Solid: 1.25 mg; 5 mg
    Section
    Antihypertensive medicines
    • Oral > Solid: 1.25 mg; 5 mg
  84. Bortezomib General information
    Section
    Targeted therapies
    • Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection
  85. Bromocriptine General information
    Section
    Antiparkinsonism medicines
    • Oral > Solid: 2.5 mg; 5 mg
  86. Budesonide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 100 µg per dose; 200 µg per dose
    Indications
    Section
    Ear, nose and throat medicines [c]
    • Local > Nasal > Spray: 100 µg per dose
  87. Budesonide + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > dry powder: 100 µg + 6 µg per dose; 200 µg + 6 µg per dose
    Indications
  88. Budesonide + salmeterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  89. Bumetanide General information
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to furosemide for Heart failure
    Section
    Diuretics
    Indications
    Therapeutic equivalent to furosemide for Anuria or oliguria Therapeutic equivalent to furosemide for Oedema
  90. Bupivacaine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 0.5% in 4 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > General injections > unspecified: 0.25% in vial (hydrochloride); 0.5% in vial (hydrochloride)
  91. Buprenorphine General information
    Section
    Medicines for disorders due to psychoactive substance use
    Indications
    Therapeutic equivalent to methadone for Opioid dependence
  92. Bupropion General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Solid: 150 mg sustained-release (hydrochloride)
  93. C1 esterase inhibitor General information
    Section
    Plasma-derived medicines
    • Parenteral > General injections > IV: 500 IU in vial powder for injection
  94. Cabergoline General information
    Section
    Antiparkinsonism medicines
    • Oral > Solid: 0.5 mg
  95. Caffeine citrate General information
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
    • Oral > Liquid: 20 mg per mL (equivalent to 10 mg caffeine base per mL)
  96. Calamine General information
    Section
    Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Lotion:
    Indications
  97. Calcipotriol General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Cream: 50 µg per mL (0.005%)
    • Local > Topical > Lotion: 50 µg per mL (0.005%)
    • Local > Topical > Ointment: 50 µg per mL (0.005%)
  98. Calcitriol General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    Indications
  99. Calcium General information
    Section
    Vitamins and minerals
    • Oral > Solid: 500 mg (elemental calcium)
  100. Calcium gluconate General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
    Indications
    Section
    Vitamins and minerals
    • Parenteral > General injections > IV: 100 mg per mL in 10 mL ampoule
  101. Canagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  102. Capreomycin General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
  103. Captopril General information
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg
    Indications
  104. Carbachol General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    Indications
  105. Carbamazepine General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 100 mg per 5 mL
    • Oral > Solid: 200 mg (scored); 100 mg (scored); 100 mg (chewable); 200 mg (chewable)
    Section
    Medicines used in bipolar disorders
    • Oral > Solid: 100 mg scored; 200 mg scored
  106. Carbetocin General information
    Section
    Uterotonics
    • Parenteral > General injections > IV: 100 µg per mL (heat stable)
  107. Carbimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    Indications
    Therapeutic equivalent to methimazole for Thyrotoxicosis
  108. Carvedilol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  109. Caspofungin General information
    Section
    Antifungal medicines
    Indications
  110. Cefalexin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (anhydrous) powder for oral liquid; 250 mg per 5 mL (anhydrous) powder for oral liquid
    • Oral > Solid: 250 mg (as monohydrate)
    • Oral > Solid: 250 mg (as monohydrate); 500 mg (as monohydrate)
  111. Cefazolin General information
    Section
    Access group antibiotics
    • Parenteral > General injections > unspecified: 1 g in vial (as sodium salt) powder for injection
  112. Cefepime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 500 mg in vial (as hydrochloride) powder for injection; 1 g in vial (as hydrochloride) powder for injection; 2 g in vial (as hydrochloride) powder for injection
  113. Cefiderocol General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial (as sulfate toxylate) powder for injection
  114. Cefixime General information
    Section
    Watch group antibiotics
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 200 mg (as trihydrate); 400 mg (as trihydrate)
  115. Cefotaxime General information
  116. Ceftaroline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 400 mg in vial (as fosamil) powder for injection; 600 mg in vial (as fosamil) powder for injection
  117. Ceftazidime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial (as pentahydrate) powder for injection; 1 g in vial (as pentahydrate) powder for injection
    Indications
    First choice
    co-prescribed with vancomycin Endophthalmitis
    Other indications
  118. Ceftazidime + avibactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial + 0.5 g in vial powder for injection
  119. Ceftolozane + tazobactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g + 0.5 g powder for injection
  120. Ceftriaxone General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > unspecified: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
    • Parenteral > General injections > IV: 250 mg in vial powder for injection (as sodium salt); 1 g in vial powder for injection (as sodium salt); 2 g in vial powder for injection (as sodium salt)
  121. Cefuroxime General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg in vial (as sodium salt) powder for injection; 750 mg in vial (as sodium salt) powder for injection; 1.5 g in vial (as sodium salt) powder for injection
    Indications
  122. Certolizumab pegol General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  123. Cetirizine General information
    Section
    Antiallergics and medicines used in anaphylaxis
  124. Chloramphenicol General information
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 1 g in vial powder for injection (sodium succinate)
    • Parenteral > General injections > IM: 500 mg in 2 mL ampoule oily suspension for injection
    • Oral > Liquid: 150 mg per 5 mL (as palmitate)
    • Oral > Solid: 250 mg capsule
    Indications
    Other indications
  125. Chlorhexidine General information
    Section
    Medicines administered to the neonate [c]
    • Local > Topical > Solution: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    • Local > Topical > Gel: 7.1% chlorhexidine digluconate (delivering 4% chlorhexidine)
    Section
    Antiseptics
    • Local > Topical > Solution: 5% (digluconate) for dilution
    Indications
  126. Chlorine base compound General information
    Section
    Disinfectants
    • Local > Topical > Powder: 0.1% available chlorine for solution
    • Local > Topical > Liquid: 0.1% available chlorine for solution
    • Local > Topical > Solid: 0.1% available chlorine for solution
  127. Chloroquine General information
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate)
    Section
    Antimalarial medicines > For curative treatment
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL ampoule (as hydrochloride, phosphate or sulfate)
    • Oral > Liquid: 50 mg per 5 mL syrup (as phosphate or sulfate)
    • Oral > Solid: 150 mg tablet (as phosphate or sulfate); 100 mg tablet (as phosphate or sulfate)
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 100 mg tablet (as phosphate or sulfate); 150 mg tablet (as phosphate or sulfate)
  128. Chlorothiazide General information
    Section
    Antihypertensive medicines
    Indications
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  129. Chloroxylenol General information
    Section
    Disinfectants
    • Local > Topical > Solution: 4.8%
  130. Chlorpromazine General information
    Section
    Medicines used in psychotic disorders
    • Oral > Liquid: 25 mg per 5 mL (hydrochloride)
    • Oral > Solid: 100 mg (hydrochloride); 10 mg (hydrochloride); 25 mg (hydrochloride); 50 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 25 mg per mL in 2 mL ampoule (hydrochloride)
  131. Chlortalidone General information
    Section
    Antihypertensive medicines
    Indications
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  132. Chlortetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Infectious blepharitis Therapeutic equivalent to tetracycline for Trachoma
  133. Cholera vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  134. Ciclesonide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  135. Ciclosporin General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
    • Oral > Solid: 25 mg
  136. Cimetidine General information
    Section
    Antiulcer medicines
    • Oral > Solid: 200 mg
    • Parenteral > General injections > unspecified: 200 mg in 2 mL ampoule
  137. Ciprofloxacin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL (as hyclate)
    • Oral > Liquid: 250 mg per 5 mL (anhydrous)
    • Oral > Solid: 250 mg (as hydrochloride)
    • Oral > Solid: 250 mg (as hydrochloride); 500 mg (as hydrochloride)
    Section
    Ear, nose and throat medicines [c]
    • Local > Otological > drops: 0.3% (as hydrochloride)
  138. Citalopram General information
    Section
    Medicines used in depressive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Depressive disorders
  139. Clarithromycin General information
    Section
    Watch group antibiotics
    • Oral > Solid: 500 mg
    • Oral > Liquid: 125 mg per 5 mL powder for oral liquid; 250 mg per 5 mL powder for oral liquid
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection
  140. Clindamycin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 75 mg per 5 mL (as palmitate hydrochloride)
    • Oral > Solid: 150 mg (as hydrochloride) capsule
    • Parenteral > General injections > unspecified: 150 mg per mL (as phosphate) injection
    • Parenteral > General injections > IV: 150 mg per mL (as phosphate); 600 mg per 4 mL (as phosphate); 900 mg per 6 mL (as phosphate)
    • Oral > Solid: 150 mg (as hydrochloride)
  141. Clofazimine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 100 mg; 50 mg
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg; 50 mg
    Indications
  142. Clomifene General information
    Section
    Ovulation inducers
    • Oral > Solid: 50 mg (citrate)
  143. Clomipramine General information
    Section
    Medicines used for obsessive compulsive disorders
    • Oral > Solid: 10 mg (hydrochloride); 25 mg (hydrochloride)
  144. Clonazepam General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Solid: 500 µg
  145. Clopidogrel General information
    Section
    Anti-platelet medicines
    • Oral > Solid: 75 mg; 300 mg
  146. Clotrimazole General information
    Section
    Antifungal medicines
    • Local > Topical > Other: 1% vaginal cream; 10% vaginal cream; 100 mg vaginal tablet; 500 mg vaginal tablet
  147. Cloxacillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 125 mg per 5 mL (as sodium salt) powder for oral liquid
    • Oral > Solid: 500 mg (as sodium salt) capsule; 1 g (as sodium salt) capsule
    • Parenteral > General injections > unspecified: 500 mg in vial (as sodium salt) powder for injection
  148. Clozapine General information
    Section
    Medicines used in psychotic disorders
    • Oral > Solid: 25 mg; 50 mg; 100 mg; 200 mg
  149. Coagulation factor IX complex General information
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection; 1000 IU in vial powder for injection
  150. Coagulation factor VIII General information
    Section
    Blood coagulation factors
    • Parenteral > General injections > IV: 500 IU in vial powder for injection
    Indications
  151. Coal tar General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Solution: 5%
  152. Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  153. Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg
  154. Cobimetinib General information
    Section
    Targeted therapies
    Indications
  155. Codeine General information
    Section
    Opioid analgesics
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
    Section
    Antitussives
    • Oral > Solid: 10 mg tablet (codeine phosphate)
    Indications
    Section
    Medicines for diarrhoea
    • Oral > Solid: 30 mg tablet (codeine phosphate)
    Indications
  156. Colchicine General information
    Section
    Medicines used to treat gout
    • Oral > Solid: 0.5 mg
    Indications
  157. Colecalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 400 IU per mL
    • Oral > Solid: 400 IU; 1000 IU
  158. Colistin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > unspecified: 1 million IU in vial (as colistemethate sodium)
  159. Compound sodium lactate solution General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: injectable solution
  160. Copper-containing intrauterine device General information
  161. Crizotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 200 mg; 250 mg
  162. Cyanocobalamin General information
    Section
    Antianaemia medicines
    • .
  163. Cyclizine General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 50 mg tablet
    • Parenteral > General injections > unspecified: 50 mg per mL
    Indications
  164. Cyclopentolate General information
    Section
    Diagnostic agents > Ophthalmic medicines
    Indications
    Therapeutic equivalent to tropicamide for Cycloplegic drug
    Section
    Ophthalmological preparations > Mydriatics
    Indications
    Therapeutic equivalent to atropine for Anterior uveitis
  165. Cyclophosphamide General information
  166. Cycloserine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg; 125 mg
  167. Dabigatran General information
    Section
    Medicines affecting coagulation
    • Oral > Solid: 110 mg; 150 mg
  168. Dabrafenib General information
    Section
    Targeted therapies
    • Oral > Solid: 50 mg; 75 mg
  169. Dacarbazine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 100 mg in vial powder for injection
    Indications
  170. Daclatasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 30 mg tablet (as hydrochloride); 60 mg tablet (as hydrochloride)
  171. Daclatasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 60 mg + 400 mg
  172. Dalteparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  173. Dapagliflozin General information
    Section
    Oral hypoglycaemic agents
    Indications
    Therapeutic equivalent to empagliflozin for Type 2 diabetes mellitus
  174. Dapsone General information
    Section
    Antileprosy medicines
    • Oral > Solid: 100 mg tablet; 50 mg tablet; 25 mg tablet
    Indications
  175. Daptomycin General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 350 mg in vial powder for injection; 500 mg in vial powder for injection
  176. Daratumumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL
  177. Darbepoetin alfa General information
    Section
    Antianaemia medicines
  178. Darunavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg
  179. Dasabuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 250 mg tablet
  180. Dasatinib General information
    Section
    Targeted therapies
    • Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet
  181. Daunorubicin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (hydrochloride) powder for injection
  182. Deferasirox General information
    Section
    Other medicines for haemoglobinopathies
  183. Deferoxamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
    Section
    Other medicines for haemoglobinopathies
    • Parenteral > General injections > unspecified: 500 mg in vial powder for injection (mesilate)
  184. Delafloxacin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 300 mg lyophilized powder for injection
    • Oral > Solid: 450 mg
  185. Delamanid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg tablet; 25 mg tablet (dispersible)
  186. Dengue vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  187. Desmopressin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 4 µg per mL in 1 mL ampoule (acetate)
    • Local > Nasal > Spray: 10 µg per dose (acetate)
  188. Dexamethasone General information
    Section
    Other medicines administered to the mother
    • Parenteral > General injections > unspecified: 4 mg per mL (dexamethasone phosphate (as sodium))
    Section
    Hormones and antihormones
    • Oral > Solid: 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosophate salt)
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 2 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Indications
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
    Section
    Antiemetic medicines
    • Oral > Liquid: 0.5 mg per 5 mL; 2 mg per 5 mL
    • Oral > Solid: 0.5 mg; 0.75 mg; 1.5 mg; 4 mg
    • Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
  189. Dextran 40 General information
    Section
    Plasma substitutes
    • .
    Indications
  190. Dextran 70 General information
    Section
    Plasma substitutes
    • Parenteral > General injections > IV: 6% injectable solution
    Indications
  191. Diazepam General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per 5 mL
    • Oral > Solid: 5 mg; 10 mg
    • Local > Rectal > Solution: 2.5 mg; 5 mg; 10 mg
    • Parenteral > General injections > unspecified: 5 mg per mL
    Indications
    Section
    Medicines for anxiety disorders
    • Oral > Solid: 5 mg (scored); 2 mg (scored)
    Indications
    Section
    Anticonvulsants/antiepileptics
    • Local > Rectal > Gel: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes
    • Local > Rectal > Solution: 5 mg per mL in 0.5 mL tubes; 5 mg per mL in 2 mL tubes; 5 mg per mL in 4 mL tubes
    Indications
  192. Diazoxide General information
    Section
    Medicines for hypoglycaemia
    • Oral > Liquid: 50 mg per mL
    • Oral > Solid: 50 mg
  193. Didanosine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution
    • Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule
  194. Diethylcarbamazine General information
    Section
    Antifilarials
    • Oral > Solid: 50 mg tablet (dihydrogen citrate); 100 mg tablet (dihydrogen citrate)
  195. Digitoxin General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 0.2 mg in 1 mL ampoule
    • Oral > Solid: 50 µg; 100 µg
    Indications
  196. Digoxin General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 250 µg per mL in 2 mL ampoule
    • Oral > Liquid: 50 µg per mL
    • Oral > Solid: 62.5 µg; 250 µg
    Indications
  197. Dihydroartemisinin + piperaquine phosphate General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 40 mg + 320 mg tablet; 20 mg + 160 mg tablet
  198. Dihydroergocryptine mesylate General information
    Section
    Antiparkinsonism medicines
    • Oral > Solid:
  199. Diloxanide General information
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Solid: 500 mg (furoate)
    Indications
  200. Dimercaprol General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IM: 50 mg per mL in 2 mL ampoule
  201. Diphtheria antitoxin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > General injections > IM: 10000 IU in vial; 20000 IU in vial
  202. Diphtheria vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  203. Diphtheria-pertussis-tetanus vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  204. Diphtheria-tetanus vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  205. Docusate sodium General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 50 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg capsule
    Indications
  206. Dolasetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  207. Dolutegravir General information
    Section
    Antiretrovirals > Integrase inhibitors
    • Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)
  208. Dolutegravir + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  209. Dopamine General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 40 mg per mL in 5 mL vial (hydrochloride)
  210. Doxycycline General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL (anhydrous); 50 mg per 5 mL (anhydrous)
    • Oral > Solid: 50 mg (as hyclate); 100 mg (as hyclate)
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection
    • Oral > Solid: 100 mg (as hyclate)
    • Oral > Solid: 100 mg (as hyclate); 50 mg (as hyclate)
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 100 mg (hydrochloride or hyclate); 100 mg dispersible tablet (as monohydrate)
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 100 mg (hydrochloride or hyclate)
  211. Durvalumab General information
    Section
    Immunomodulators
  212. Edoxaban General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to dabigatran for Venous thromboembolism Therapeutic equivalent to dabigatran for Other specified atrial fibrillation
  213. Efavirenz General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Solid: 600 mg tablet
  214. Efavirenz + emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  215. Efavirenz + lamivudine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate, equivalent to 245 mg tenofovir disoproxil)
  216. Eflornithine General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 200 mg per mL in 100 mL bottle (hydrochloride)
  217. Elbasvir + grazoprevir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 50 mg + 100 mg
  218. Empagliflozin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 10 mg; 25 mg
  219. Emtricitabine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 10 mg per mL
    • Oral > Solid: 200 mg
  220. Emtricitabine + rilpivirine + tenofovir alafenamide General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 25 mg + 25 mg
  221. Emtricitabine + rilpivirine + tenofovir disoproxil fumarate General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  222. Emtricitabine + tenofovir General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)
  223. Emtricitabine + tenofovir alafenamide General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg
  224. Enalapril General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)
    Section
    Medicines used in heart failure
    • Oral > Solid: 2.5 mg (as hydrogen maleate); 5 mg (as hydrogen maleate)
    Indications
  225. Encorafenib General information
    Section
    Targeted therapies
    Indications
  226. Enoxaparin General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 120 mg per 0.8 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
    • Parenteral > General injections > SC: 20 mg per 0.2 mL in prefilled syringe; 40 mg per 0.4 mL in prefilled syringe; 60 mg per 0.6 mL in prefilled syringe; 80 mg per 0.8 mL in prefilled syringe; 100 mg per 1 mL in prefilled syringe; 120 mg per 0.8 mL in prefilled syringe; 150 mg per 1 mL in prefilled syringe; 150 mg per 1 mL in ampoule; 20 mg per 0.2 mL in ampoule; 40 mg per 0.4 mL in ampoule; 60 mg per 0.6 mL in ampoule; 80 mg per 0.8 mL in ampoule; 120 mg per 0.8 mL in ampoule; 100 mg per 1 mL in ampoule
  227. Entecavir General information
    Section
    Medicines for hepatitis B > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 0.05 mg per mL
    • Oral > Solid: 0.5 mg; 1 mg
  228. Enzalutamide General information
    Section
    Hormones and antihormones
    • Oral > Solid: 40 mg
  229. Ephedrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 30 mg per mL in 1 mL ampoule (ephedrine hydrochloride)
  230. Epinephrine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 100 µg per mL in 10 mL ampoule (as acid tartrate or hydrochloride)
    Indications
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (as hydrochloride)
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (as hydrochloride or hydrogen tartrate)
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 1 mg in 1 mL ampoule (as hydrochloride or hydrogen tartrate)
    Indications
  231. Epoetin alfa General information
    Section
    Antianaemia medicines
  232. Epoetin beta General information
    Section
    Antianaemia medicines
  233. Epoetin theta General information
    Section
    Antianaemia medicines
  234. Equine rabies immunoglobulin General information
    Section
    Immunologicals > Sera, immunoglobulins and monoclonal antibodies
    • Parenteral > Locoregional injections > Intradermal: 150 IU per mL in vial; 200 IU per mL in vial; 300 IU per mL in vial; 400 IU per mL in vial
    Indications
  235. Eravacycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 50 mg lyophilized powder for injection
  236. Ergocalciferol General information
    Section
    Vitamins and minerals
    • Oral > Liquid: 250 µg per mL (10 000 IU per mL)
    • Oral > Solid: 1.25 mg (50 000 IU)
  237. Ergometrine General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 200 µg in 1 mL ampoule (hydrogen maleate)
  238. Erlotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 100 mg; 150 mg
  239. Erythromycin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial powder for injection (as lactobionate)
    • Oral > Liquid: 125 mg per 5 mL (as stearate or ethylsuccinate)
    • Oral > Solid: 250 mg (as stearate or ethylsuccinate)
    Indications
    Second choice
    Therapeutic equivalent to clarithromycin for Acute pharyngitis
    Other indications
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Ointment: 0.5%
  240. Erythropoiesis-stimulating agents General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > unspecified: 1000 IU per 0.5 mL pre-filled syringe; 2000 IU per 0.5 mL pre-filled syringe; 3000 IU per 0.3 mL pre-filled syringe; 4000 IU per 0.4 mL pre-filled syringe; 5000 IU per 0.5 mL pre-filled syringe; 6000 IU per 0.6 mL pre-filled syringe; 8000 IU per 0.8 mL pre-filled syringe; 10000 IU per 1 mL pre-filled syringe; 20000 IU per 0.5 mL pre-filled syringe; 40000 IU per 1 mL pre-filled syringe
  241. Escitalopram General information
    Section
    Medicines used in depressive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Depressive disorders
  242. Estradiol cypionate + medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 5 mg + 25 mg
  243. Etanercept General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  244. Ethambutol General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 25 mg per mL
    • Oral > Solid: 100 mg (hydrochloride); 400 mg (hydrochloride); 100 mg tablet (dispersible)
    • Parenteral > General injections > IV: 1000 mg per 10 mL; 2000 mg per 20 mL
  245. Ethambutol + isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg + 150 mg tablet
    Indications
  246. Ethambutol + isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 400 mg + 150 mg tablet
    Indications
  247. Ethambutol + isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 275 mg + 75 mg + 150 mg tablet
    Indications
  248. Ethanol General information
    Section
    Antiseptics
    • Local > Topical > Solution: 70% (denatured)
  249. Ether General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation > solution:
  250. Ethinylestradiol + etonogestrel General information
    Section
    Intravaginal contraceptives
    • Local > Vaginal > vaginal ring: 2.7 mg + 11.7 mg
  251. Ethinylestradiol + levonorgestrel General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 50 µg + 250 µg [4]
    • Oral > Solid: 30 µg + 150 µg
  252. Ethinylestradiol + norethisterone General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 35 µg + 1 mg
  253. Ethionamide General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 125 mg tablet; 250 mg tablet; 125 mg tablet (dispersible)
  254. Ethosuximide General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg
  255. Etonogestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 68 mg single rod
  256. Everolimus General information
    Section
    Targeted therapies
    • Oral > Solid: 2.5 mg; 5 mg; 7.5 mg; 10 mg; 2 mg tablet (dispersible); 3 mg tablet (dispersible); 5 mg tablet (dispersible)
  257. Fentanyl General information
    Section
    Opioid analgesics
    • Local > Topical > Transdermal patch: 12 µg/hour; 25 µg/hour; 50 µg/hour; 75 µg/hour; 100 µg/hour
  258. Ferrous salt General information
    Section
    Antianaemia medicines
    • Oral > Liquid: 25 mg per mL iron (as sulfate)
    • Oral > Solid: 60 mg iron
  259. Ferrous salt + folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 60 mg iron + 400 µg tablet
    • Oral > Solid: 60 mg iron + 2.8 mg
  260. Fexinidazole General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Oral > Solid: 600 mg
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 600 mg
  261. Fexofenadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
  262. Fifth generation cephalosporins General information
    Section
    Reserve group antibiotics
    • .
  263. Filgrastim General information
    Section
    Immunomodulators
    • Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial
  264. Fingolimod General information
    Section
    Immunomodulators for non-malignant disease
    • Oral > Solid: 0.25 mg; 0.5 mg
  265. Fluconazole General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2 mg per mL in vial
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 50 mg capsule
  266. Flucytosine General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 2.5 g per 250 mL infusion
    • Oral > Solid: 250 mg capsule
    Indications
  267. Fludarabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
    • Oral > Solid: 10 mg tablet (fludarabine phosphate)
  268. Fludrocortisone General information
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 100 µg (acetate)
  269. Flunisolide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  270. Fluorescein General information
    Section
    Diagnostic agents > Ophthalmic medicines
    • Local > Ophthalmological > Solution (eye drops): 1% (sodium salt)
    Indications
  271. Fluoride General information
    Section
    Dental preparations
    • Local > Dental > Paste: 1000 to 1500 ppm fluoride (any type)
    • Local > Dental > Cream: 1000 to 1500 ppm fluoride (any type)
    • Local > Dental > Gel: 1000 to 1500 ppm fluoride (any type)
    • Local > Dental > Other: In other appropriate topical formulations
    Indications
  272. Fluorouracil General information
    Section
    Dermatological medicines (topical) > Medicines affecting skin differentiation and proliferation
    • Local > Topical > Ointment: 5%
    Indications
  273. Fluoxetine General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 20 mg (as hydrochloride)
    Indications
    Section
    Medicines used in depressive disorders
    • Oral > Solid: 20 mg (as hydrochloride)
  274. Fluphenazine General information
    Section
    Medicines used in psychotic disorders
    • Parenteral > General injections > IM: 25 mg per mL in ampoule (decanoate); 25 mg per mL in ampoule (enanthate)
  275. Flutamide General information
    Section
    Hormones and antihormones
    Indications
  276. Fluticasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  277. Fluticasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  278. Fluticasone furoate + vilanterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  279. Fluvastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  280. Fluvoxamine General information
    Section
    Medicines used in depressive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Depressive disorders
  281. Folic acid General information
    Section
    Antianaemia medicines
    • Oral > Solid: 1 mg tablet; 5 mg tablet
    • Oral > Solid: 400 µg
  282. Fomepizole General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 5 mg per mL in 20 mL ampoule (sulfate); 1 g per mL in 1.5 mL ampoule (base)
  283. Fosfomycin (injection) General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 g in vial (as sodium) powder for injection; 4 g in vial (as sodium) powder for injection
  284. Fourth generation cephalosporins General information
    Section
    Watch group antibiotics
    • .
  285. Fresh-frozen plasma General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  286. Fulvestrant General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 250 mg per 5 mL
  287. Furosemide General information
    Section
    Medicines used in heart failure
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL
    • Oral > Solid: 40 mg
    Indications
    Section
    Diuretics
    • Parenteral > General injections > IV: 10 mg per mL in 2 mL ampoule
    • Oral > Liquid: 20 mg per 5 mL
    • Oral > Solid: 40 mg; 10 mg; 20 mg
  288. Gabapentin General information
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Solid: 100 mg; 200 mg; 300 mg; 400 mg; 600 mg; 800 mg
    Indications
  289. Gallamine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Parenteral > General injections > IV: 40 mg per mL in 2 mL ampoule (gallamine triethiodide)
    Indications
  290. Gatifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
  291. Gefitinib General information
    Section
    Targeted therapies
  292. Gemcitabine General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection
  293. Gentamicin General information
  294. Glass ionomer cement General information
    Section
    Dental preparations
    • Local > Dental > Powder + liquid: Single-use capsules: 0.4 g powder + 0.09 mL liquid; Multi-use bottle: powder + liquid
    Indications
  295. Glatiramer acetate General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > SC: 20 mg per mL; 40 mg per mL
  296. Glecaprevir + pibrentasvir General information
    Section
    Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 100 mg + 40 mg tablet; 50 mg + 20 mg granules
  297. Glibenclamide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 5 mg; 2.5 mg
  298. Gliclazide General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 30 mg controlled-release; 60 mg controlled-release; 80 mg controlled-release
  299. Glucagon General information
    Section
    Medicines for hypoglycaemia
    • Parenteral > General injections > unspecified: 1 mg per mL
  300. Glucose General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 5% isotonic; 10% hypertonic
    • Parenteral > General injections > IV: 50% hypertonic
  301. Glucose + sodium chloride General information
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Parenteral
    • Parenteral > General injections > IV: 4% + 0.18% (equivalent to Na+ 30 mmol/L and Cl- 30 mmol/L; 5% + 0.9% (equivalent to Na+ 150 mmol/L and Cl- 150 mmol/L); 5% + 0.45% (equivalent to Na+ 75 mmol/L and Cl- 75 mmol/L)
  302. Glutaral General information
    Section
    Disinfectants
    • Local > Topical > Solution: 2%
  303. Glyceryl trinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 500 µg sublingual tablet
    Indications
  304. Glycopyrronium General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
  305. Golimumab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  306. Goserelin General information
    Section
    Hormones and antihormones
    Indications
  307. Granisetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  308. Griseofulvin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 125 mg per 5 mL
    • Oral > Solid: 125 mg; 250 mg
    Indications
  309. Haemophilus influenzae type b vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  310. Haloperidol General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 0.5 mg; 2 mg; 5 mg
    • Parenteral > General injections > unspecified: 5 mg per mL in 1-mL ampoule
    Indications
    Section
    Medicines used in psychotic disorders
    • Parenteral > General injections > IM: 5 mg per mL in ampoule
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 2 mg; 0.5 mg; 5 mg
  311. Halothane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
  312. Heparin sodium General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 1000 IU per mL in 5 mL ampoule; 20000 IU per mL in 5 mL ampoule; 5000 IU per mL in 5 mL ampoule
  313. Hepatitis a vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  314. Hepatitis b vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  315. Homatropine General information
    Section
    Ophthalmological preparations > Mydriatics
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrobromide)
    Indications
  316. Hpv vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  317. Hydralazine General information
    Section
    Antihypertensive medicines
    • Parenteral > General injections > IV: 20 mg in ampoule powder for injection (hydrochloride)
    • Oral > Solid: 50 mg tablet; 25 mg tablet (hydrochloride)
    • Oral > Solid: 50 mg (hydrochloride); 25 mg (hydrochloride)
  318. Hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg; 12.5 mg
    Section
    Medicines used in heart failure
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 25 mg
    Indications
    Section
    Diuretics
    • Oral > Solid: 25 mg
    Indications
  319. Hydrocortisone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)
    Section
    Adrenal hormones and synthetic substitutes
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Section
    Ophthalmological preparations > Anti-inflammatory agents
    • Local > Ophthalmological > Ointment: 1% (acetate)
    Section
    Antiallergics and medicines used in anaphylaxis
    • Parenteral > General injections > unspecified: 100 mg in vial powder for injection (as sodium succinate)
    Indications
    Section
    Anti-inflammatory medicines
    • Local > Rectal > Suppository: 25 mg (acetate)
    • Local > Rectal > Retention enema: 100 mg per 60 mL
    Section
    Dermatological medicines (topical) > Anti-inflammatory and antipruritic medicines
    • Local > Topical > Cream: 1% (acetate)
    • Local > Topical > Ointment: 1% (acetate)
  320. Hydromorphone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  321. Hydroxocobalamin General information
    Section
    Antianaemia medicines
    • Parenteral > General injections > IM: 1 mg per mL in 1 mL ampoule (as acetate); 1 mg per mL in 1 mL ampoule (as hydrochloride); 1 mg per mL in 1 mL ampoule (as sulfate)
  322. Hydroxycarbamide General information
    Section
    Other medicines for haemoglobinopathies
    • Oral > Solid: 200 mg; 500 mg; 1 g
    Section
    Cytotoxic medicines
    • Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g
  323. Hydroxychloroquine General information
    Section
    Antimalarial medicines > For chemoprevention
    Indications
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 200 mg (as sulfate)
  324. Hyoscine butylbromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > unspecified: 20 mg per mL injection
    Indications
  325. Hyoscine hydrobromide General information
    Section
    Medicines for other common symptoms in palliative care
    • Local > Topical > Transdermal patch: 1 mg per 72 hours transdermal patch
    • Parenteral > General injections > unspecified: 400 µg per mL injection; 600 µg per mL injection
    Indications
  326. Hypochlorous acid General information
    Section
    Antiseptics
    • Local > Topical > Solution:
  327. Ibrutinib General information
    Section
    Targeted therapies
    • Oral > Solid: 140 mg
  328. Ibuprofen General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Solid: 200 mg; 400 mg
    Indications
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 200 mg per 5 mL
    • Oral > Solid: 200 mg; 400 mg; 600 mg
    Indications
    Section
    Medicines administered to the neonate [c]
    • Parenteral > General injections > IV: 5 mg per mL
  329. Idoxuridine General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.1%
    • Local > Ophthalmological > Ointment: 0.2%
  330. Ifosfamide General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
    • Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection
  331. Imipenem + cilastatin General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 250 mg (as monohydrate) + 250 mg (as sodium salt) powder for injection; 500 mg (as monohydrate) + 500 mg (as sodium salt) powder for injection
    Section
    Antituberculosis medicines
    Indications
  332. Indapamide General information
    Section
    Antihypertensive medicines
    Indications
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to hydrochlorothiazide for Heart failure
  333. Indinavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 400 mg (as sulfate)
  334. Indometacin General information
    Section
    Medicines administered to the neonate [c]
    Indications
    Therapeutic equivalent to ibuprofen for Patent arterial duct
  335. Infliximab General information
    Section
    Immunomodulators for non-malignant disease
    Indications
    Therapeutic equivalent to adalimumab for Axial spondyloarthritis Therapeutic equivalent to adalimumab for Crohn disease site Therapeutic equivalent to adalimumab for Juvenile idiopathic arthritis Therapeutic equivalent to adalimumab for Rheumatoid arthritis
  336. Influenza vaccine (seasonal) General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
  337. Insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial (soluble); 100 IU per mL in 10 mL vial (soluble)
  338. Insulin analogues General information
    Section
    Insulins
    • Not specified
  339. Insulin degludec General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
  340. Insulin detemir General information
    Section
    Insulins
  341. Insulin glargine General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 units per mL
  342. Intermediate-acting insulin General information
    Section
    Insulins
    • Parenteral > General injections > SC: 40 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin; 100 IU per mL in 10 mL vial as compound insulin zinc suspension or isophane insulin
  343. Intraperitoneal dialysis solution General information
    Section
    Peritoneal dialysis solution
    • parenteral solution
  344. Iodine General information
    Section
    Vitamins and minerals
    • Parenteral > General injections > IM: 0.5 mL (240 mg iodine) iodized oil in ampoule; 1 mL (480 mg iodine) iodized oil in ampoule
    • Oral > Liquid: 1 mL (480 mg iodine) iodized oil in ampoule; 0.5 mL (240 mg iodine) iodized oil in ampoule; 0.57 mL (308 mg iodine) iodized oil in dispenser bottle
    • Oral > Solid: 190 mg
    Section
    Antiseptics
    Indications
    Therapeutic equivalent to povidone iodine for Povidone iodine
  345. Iohexol General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > unspecified: 140 to 350 mg iodine per mL in 5 mL ampoule; 140 to 350 mg iodine per mL in 10 mL ampoule; 140 to 350 mg iodine per mL in 20 mL ampoule
  346. Ipecacuanha General information
    Section
    Antidotes and other substances used in poisonings > Non-specific
    • Oral > Liquid: 0.14% ipecacuanha alkaloids calculated as emetine
  347. Ipratropium bromide General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    • Respiratory > Inhalation > aerosol: 20 µg per dose
  348. Irinotecan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial
  349. Isoflurane General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
  350. Isoniazid General information
    Section
    Antituberculosis medicines
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 100 mg tablet; 100 mg tablet (dispersible); 300 mg tablet
    • Parenteral > General injections > IV: 100 mg per mL
  351. Isoniazid + pyrazinamide + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 150 mg + 75 mg tablet (dispersible)
    Indications
  352. Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim General information
    Section
    Medicines for prevention of HIV-related opportunistic infections
    • Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)
  353. Isoniazid + rifampicin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 50 mg + 75 mg tablet (dispersible); 75 mg + 150 mg tablet; 150 mg + 300 mg tablet
    Indications
  354. Isoniazid + rifapentine General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 300 mg + 300 mg tablet (scored)
  355. Isoprenaline General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 µg per mL in ampoule (hydrochloride)
    • Oral > Solid: 10 mg (hydrochloride or sulfate); 15 mg (hydrochloride or sulfate)
  356. Isosorbide dinitrate General information
    Section
    Antianginal medicines
    • Oral > Solid: 5 mg sublingual tablet
    Indications
  357. Ivermectin General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 3 mg tablet (scored)
    Section
    Antifilarials
    • Oral > Solid: 3 mg tablet (scored)
    Section
    Medicines for ectoparasitic infections
    • Oral > Solid: 3 mg tablet (scored)
    Indications
  358. Japanese encephalitis vaccine General information
    Section
    Recommendations for certain regions
    • All vaccines should comply with the WHO requirements for biological substances.
  359. Kanamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  360. Kanamycin (injection) General information
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 1000 mg powder for injection (vial)
  361. Ketamine General information
    Section
    General anaesthetics and oxygen > Injectable medicines
    • Parenteral > General injections > unspecified: 50 mg per mL in 10 mL vial (as hydrochloride)
  362. Lactulose General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 3.1 to 3.7 g per 5 mL oral liquid
    Indications
  363. Lamivudine General information
    Section
    Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL
    • Oral > Solid: 150 mg tablet
  364. Lamivudine + nevirapine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg Tablet
  365. Lamivudine + zidovudine General information
    Section
    Fixed-dose combinations of antiretrovirals
    • Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet
  366. Lamotrigine General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet; 200 mg tablet; 2 mg tablet (chewable, dispersible); 5 mg tablet (chewable, dispersible); 25 mg tablet (chewable, dispersible); 50 mg tablet (chewable, dispersible); 100 mg tablet (chewable, dispersible); 200 mg tablet (chewable, dispersible)
  367. Latanoprost General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 50 µg per mL eye drops
  368. Ledipasvir + sofosbuvir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 90 mg + 400 mg tablet
  369. Lenalidomide General information
    Section
    Immunomodulators
    • Oral > Solid: 25 mg
  370. Leuprorelin General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe
  371. Levamisole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 50 mg tablet; 150 mg tablet (as hydrochloride)
    Indications
  372. Levodopa General information
    Section
    Antiparkinsonism medicines
    • Oral > Solid: 250 mg
  373. Levodopa + benserazide General information
    Section
    Antiparkinsonism medicines
    Indications
    Therapeutic equivalent to levodopa + carbidopa for Parkinson disease
  374. Levodopa + carbidopa General information
    Section
    Antiparkinsonism medicines
    • Oral > Solid: 100 mg + 10 mg tablet; 250 mg + 25 mg tablet; 100 mg + 25 mg tablet
  375. Levofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 250 mg tablet; 500 mg tablet; 750 mg tablet; 100 mg tablet (dispersible)
  376. Levonorgestrel General information
    Section
    Intrauterine devices
    • Intrauterine system with reservoir containing 52 mg of levonorgestrel.
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 750 µg [2]; 1.5 mg [1]
    • Oral > Solid: 30 µg
  377. Levonorgestrel-releasing implant General information
    Section
    Implantable contraceptives
    • Implant > Subdermal: 75 mg per rod (two-rods)
  378. Levothyroxine General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 50 µg (sodium salt); 100 µg (sodium salt); 25 µg (sodium salt)
    Indications
  379. Lidocaine General information
    Section
    Antiarrhythmic medicines
    • Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule (hydrochloride)
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Spinal anaesthesia: 5% in 2 mL ampoule (hydrochloride) + 7.5% glucose solution
    • Parenteral > Locoregional injections > Other: 1% in vial (hydrochloride); 2% in vial (hydrochloride)
    • Local > Topical > unspecified: 2 to 4% (hydrochloride)
  380. Lidocaine + epinephrine General information
    Section
    Local anaesthetics
    • Parenteral > Locoregional injections > Other: 1% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial; 2% (lidocaine hydrochloride OR lidocaine sulfate) + 1:200 000 epinephrine in vial
    • Local > Dental > Cartridge: 2% (lidocaine hydrochloride) + 1:80 000 epinephrine
  381. Lindane General information
    Section
    Dermatological medicines (topical) > Scabicides and pediculicides
    • Local > Topical > Cream: 1%
    • Local > Topical > Lotion: 1%
    Indications
  382. Linezolid General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 2 mg per mL in 300 mL bag
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 400 mg tablet; 600 mg tablet
    Section
    Antituberculosis medicines
    • Oral > Liquid: 100 mg per 5 mL powder for oral liquid
    • Oral > Solid: 600 mg tablet; 150 mg tablet (dispersible)
  383. Lisinopril + amlodipine General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 5 mg; 20 mg + 5 mg; 20 mg + 10 mg
  384. Lisinopril + hydrochlorothiazide General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg + 12.5 mg; 20 mg + 12.5 mg; 20 mg + 25 mg
  385. Lithium carbonate General information
    Section
    Medicines used in bipolar disorders
    • Oral > Solid: 300 mg
  386. Long-acting insulin analogues General information
    Section
    Insulins
    • Parenteral > General injections > SC: 100 IU per mL in 3 mL cartridge; 100 IU per mL in 3 mL pre-filled syringe
  387. Loperamide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Solid: 2 mg solid oral dosage form
    Indications
  388. Lopinavir + ritonavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg
  389. Loratadine General information
    Section
    Antiallergics and medicines used in anaphylaxis
    • Oral > Liquid: 1 mg per mL
    • Oral > Solid: 10 mg
  390. Lorazepam General information
    Section
    Anticonvulsants/antiepileptics
    • Parenteral > General injections > IV: 2 mg per mL in 1 mL ampoule; 4 mg per mL in 1 mL ampoule
  391. Losartan General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Section
    Medicines used in heart failure
    • Oral > Solid: 25 mg tablet; 50 mg tablet; 100 mg tablet
    Indications
  392. Lovastatin General information
    Section
    Lipid-lowering agents
    Indications
    Therapeutic equivalent to simvastatin for Mixed hyperlipidaemia Therapeutic equivalent to simvastatin for Coronary atherosclerosis
  393. Lugol's solution General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Liquid: 13% w/v (about 130 mg/mL total iodine)
    Indications
  394. Magnesium sulfate General information
    Section
    Anticonvulsants/antiepileptics
    • Parenteral > General injections > IV: 500 mg per mL in 2 mL ampoule (equivalent to 1 g in 2 mL; 50% weight/volume)
    • Parenteral > General injections > IM: 500 mg per mL in 10 mL ampoule (equivalent to 5 g in 10 mL; 50% weight/volume)
  395. Mannitol General information
    Section
    Diuretics
    • Parenteral > General injections > IV: 10% solution; 20% solution
  396. Measles vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  397. Mebendazole General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 100 mg tablet (chewable); 500 mg tablet (chewable)
    Section
    Cysticidal medicines
    • Oral > Solid: 500 mg tablet (chewable)
  398. Medroxyprogesterone acetate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 150 mg per mL in 1 mL vial
    • Parenteral > General injections > SC: 104 mg per 0.65 mL in pre-filled syringe; 104 mg per 0.65 mL in single dose injection delivery system
    Section
    Progestogens
    • Oral > Solid: 5 mg
  399. Mefloquine General information
    Section
    Antimalarial medicines > For curative treatment
    • Oral > Solid: 250 mg tablet (hydrochloride)
    Section
    Antimalarial medicines > For chemoprevention
    • Oral > Solid: 250 mg tablet (hydrochloride)
  400. Meglumine antimoniate General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 30% in 5 mL ampoule equivalent to approximately 8.1% antimony
  401. Meglumine iotroxate General information
    Section
    Diagnostic agents > Radiocontrast media
    • Parenteral > General injections > IV: 5 to 8 g iodine (as meglumine) in 100 to 250 mL
  402. Melarsoprol General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Parenteral > General injections > IV: 3.6% in 5 mL ampoule solution (180 mg of active compound)
  403. Melphalan General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection
    • Oral > Solid: 2 mg
  404. Meningococcal meningitis vaccine General information
    Section
    Recommendations for some high-risk populations
    • All vaccines should comply with the WHO requirements for biological substances.
  405. Meropenem General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
    Section
    Antituberculosis medicines
    • Parenteral > General injections > IV: 500 mg in vial (as trihydrate) powder for injection; 1 g in vial (as trihydrate) powder for injection
  406. Meropenem + vaborbactam General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 1 g in vial + 1 g in vial powder for injection
  407. Mesalazine General information
    Section
    Anti-inflammatory medicines
    Indications
    Therapeutic equivalent to sulfasalazine for Crohn disease site Therapeutic equivalent to sulfasalazine for Ulcerative colitis
  408. Metformin General information
    Section
    Oral hypoglycaemic agents
    • Oral > Solid: 500 mg (hydrochloride)
  409. Methadone General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    Section
    Opioid analgesics
    • Oral > Liquid: 5 mg per 5 mL (methadone hydrochloride); 10 mg per 5 mL (methadone hydrochloride); 5 mg per mL concentrate for oral liquid (methadone hydrochloride); 10 mg per mL concentrate for oral liquid (methadone hydrochloride)
    • Oral > Solid: 5 mg (methadone hydrochloride); 10 mg (methadone hydrochloride)
  410. Methimazole General information
    Section
    Thyroid hormones and antithyroid medicines
    • Oral > Solid: 5 mg; 10 mg; 20 mg
    Indications
  411. Methionine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg (DL)
  412. Methoxy polyethylene glycol-epoetin beta General information
    Section
    Antianaemia medicines
  413. Methyldopa General information
    Section
    Antihypertensive medicines
    • Oral > Solid: 250 mg
  414. Methylergometrine General information
    Section
    Uterotonics
    Indications
    Therapeutic equivalent to ergometrine for Postpartum haemorrhage
  415. Methylphenidate General information
    Section
    Medicines for mental and behavioural disorders
    • Multiple formulations and strengths.
  416. Methylprednisolone General information
    Section
    Hormones and antihormones
    • Parenteral > General injections > IV: 40 mg per mL in 1 mL single-dose vial (as sodium succinate); 40 mg per mL in 5 mL multi-dose vial (as sodium succinate); 80 mg per mL in 1 mL single-dose vial (as sodium succinate)
  417. Methylthioninium chloride General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > IV: 10 mg per mL in 10 mL ampoule
  418. Metoclopramide General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
    Indications
    Section
    Antiemetic medicines
    • Oral > Liquid: 5 mg per 5 mL
    • Oral > Solid: 10 mg (hydrochloride)
    • Parenteral > General injections > unspecified: 5 mg per mL in 2 mL ampoule (hydrochloride)
  419. Metoprolol General information
    Section
    Antianginal medicines
    Indications
    Therapeutic equivalent to bisoprolol for Angina pectoris
    Section
    Medicines used in heart failure
    Indications
    Therapeutic equivalent to bisoprolol for Heart failure
    Section
    Antiarrhythmic medicines
    Indications
    Therapeutic equivalent to bisoprolol for Cardiac arrhythmia
    Section
    Antihypertensive medicines
    Indications
    Therapeutic equivalent to bisoprolol for Essential hypertension
  420. Metronidazole General information
    Section
    Access group antibiotics
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Parenteral > General injections > unspecified: 500 mg per 100 mL in vial Injection
    • Local > Rectal > Suppository: 500 mg suppository; 1 g suppository
    • Local > Rectal > Suppository: 1 g suppository; 500 mg suppository
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 200 mg per 5 mL (as benzoate)
    • Oral > Solid: 200 to 500 mg tablet
    • Parenteral > General injections > unspecified: 500 mg in 100 mL vial
    Indications
  421. Micafungin General information
    Section
    Antifungal medicines
    • Parenteral > General injections > IV: 50 mg in vial (as sodium) powder for injection; 100 mg in vial (as sodium) powder for injection
  422. Miconazole General information
    Section
    Dermatological medicines (topical) > Antifungal medicines
    • Local > Topical > Cream: 2% (nitrate)
    • Local > Topical > Ointment: 2% (nitrate)
  423. Midazolam General information
    Section
    Medicines for other common symptoms in palliative care
    • Oral > Liquid: 2 mg per mL oral liquid
    • Oral > Solid: 7.5 mg solid oral dosage form; 15 mg solid oral dosage form
    • Parenteral > General injections > unspecified: 1 mg per mL injection; 5 mg per mL injection
    Indications
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 1 mg per mL
    • Oral > Liquid: 2 mg per mL
    • Oral > Solid: 15 mg tablet; 7.5 mg tablet
    Section
    Anticonvulsants/antiepileptics
    • Parenteral > General injections > unspecified: 1 mg per mL in ampoule (for buccal administration); 10 mg per mL in ampoule (for buccal administration)
    • Local > Buccal > Solution: 5 mg per mL solution for oromucosal administration; 10 mg per mL solution for oromucosal administration
    Indications
  424. Mifepristone - misoprostol General information
    Section
    Uterotonics
    • Oral > Solid: 200 mg + 200 µg; 200 mg [1] + 200 µg [4] in co-package
    Indications
  425. Miltefosine General information
    Section
    Antileishmaniasis medicines
    • Oral > Solid: 10 mg; 50 mg
  426. Misoprostol General information
    Section
    Uterotonics
    • Oral > Solid: 200 µg
    • Local > Vaginal > tablet: 25 µg
  427. Mometasone General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide for Asthma
  428. Mometasone + formoterol General information
    Section
    Antiasthmatic and medicines for chronic obstructive pulmonary disease
    Indications
    Therapeutic equivalent to budesonide + formoterol for Asthma
  429. Morphine General information
    Section
    Preoperative medication and sedation for short-term procedures
    • Parenteral > General injections > IV: 10 mg in 1 mL ampoule (sulfate OR hydrochloride)
    Section
    Opioid analgesics
    • Oral > Liquid: 10 mg per 5 mL (morphine hydrochloride or morphine sulfate)
    • Oral > Solid: 10 mg immediate release (morphine sulfate); 10 to 200 mg slow release (morphine hydrochloride or morphine sulfate)
    • Oral > Other: 20 to 200 mg slow release granules to mix with water (morphine sulfate)
    • Parenteral > General injections > unspecified: 10 mg in 1 mL ampoule (morphine hydrochloride or morphine sulfate)
    Indications
  430. Moxifloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 400 mg tablet; 100 mg tablet (dispersible)
    • Oral > Solid: 400 mg tablet
  431. Multiple micronutrient powder General information
    Section
    Vitamins and minerals
    • Oral > Other:
  432. Multiple micronutrient supplement General information
    Section
    Other medicines administered to the mother
    • Tablet containing:
    • Vit A: 800 mcg retinol activity equivalent
    • Vit C: 70 mg
    • Vit D: 5 mcg (200 IU)
    • Vit E: 10 mg alpha tocopherol equivalent
    • Vit B1: 1.4 mg
    • Vit B2: 1.4 mg
    • Vit B3: 18 mg niacin equivalent
    • Vit B6: 1.9 mg
    • Folic acid: 400 mcg
    • Vit B12: 2.6 mcg
    • Iron: 30 mg
    • Iodine: 150 mcg
    • Zinc: 15 mg
    • Selenium: 65 mcg
    • Copper: 2 mg
  433. Mumps vaccine General information
    Section
    Recommendations for immunization programmes with certain characteristics
    • All vaccines should comply with the WHO requirements for biological substances.
  434. Mupirocin General information
    Section
    Dermatological medicines (topical) > Anti-infective medicines
    • Local > Topical > Cream: 2% (as mupirocin calcium)
    • Local > Topical > Ointment: 2%
  435. Nadroparin General information
    Section
    Medicines affecting coagulation
    Indications
    Therapeutic equivalent to enoxaparin for Acute ischaemic heart disease Therapeutic equivalent to enoxaparin for Venous thromboembolism
  436. Nalidixic acid General information
    Section
    Anti-infective medicines
    • Oral > Solid: 250 mg; 500 mg
  437. Naloxone General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Parenteral > General injections > unspecified: 400 µg per 1 mL in ampoule (naloxone hydrochloride)
  438. Natamycin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Suspension: 5% eye drops
  439. Nelfinavir General information
    Section
    Antiretrovirals > Protease inhibitors
    • Oral > Solid: 250 mg (as mesilate)
    • Oral > Other: 50 mg per g oral powder
  440. Neostigmine General information
    Section
    Muscle relaxants (peripherally-acting) and cholinesterase inhibitors
    • Oral > Solid: 15 mg (neostigmine bromide)
    • Parenteral > General injections > unspecified: 0.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate); 2.5 mg per mL in 1 mL ampoule (neostigmine metilsulfate)
  441. Netilmicin General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to gentamicin for Other specified conjunctivitis Therapeutic equivalent to gentamicin for Infectious blepharitis
  442. Nevirapine General information
    Section
    Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
    • Oral > Liquid: 50 mg per 5 mL oral solution
    • Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)
  443. Niclosamide General information
    Section
    Intestinal anthelminthics
    • Oral > Solid: 500 mg tablet (chewable)
  444. Nicotinamide General information
    Section
    Vitamins and minerals
    • Oral > Solid: 50 mg
    Indications
  445. Nicotine replacement therapy General information
    Section
    Medicines for disorders due to psychoactive substance use
    • Oral > Other: 2 mg chewing gum; 4 mg chewing gum
    • Local > Topical > Transdermal patch: 5 to 30 mg per 16 hour; 7 to 21 mg per 24 hour
  446. Nifedipine General information
    Section
    Antioxytocics (tocolytics)
    • Oral > Solid: 10 mg (immediate-release)
    Section
    Antianginal medicines
    • Oral > Solid: 10 mg
    Indications
    Section
    Antihypertensive medicines
    • Oral > Solid: 10 mg tablet; sustained-release formulations
  447. Nifurtimox General information
    Section
    Medicines for the treatment of 2nd stage African trypanosomiasis
    • Oral > Solid: 120 mg
    Section
    American trypanosomiasis
    • Oral > Solid: 30 mg tablet; 120 mg tablet; 250 mg tablet
    Indications
  448. Nilotinib General information
    Section
    Targeted therapies
    • Oral > Solid: 150 mg capsule; 200 mg capsule
  449. Nilutamide General information
    Section
    Hormones and antihormones
    Indications
  450. Nitrofurantoin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 25 mg per 5 mL oral liquid
    • Oral > Solid: 100 mg tablet
    Indications
  451. Nitrous oxide General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation:
  452. Nivolumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
  453. Norethisterone General information
    Section
    Oral hormonal contraceptives
    • Oral > Solid: 350 µg
    Section
    Progestogens
    • Oral > Solid: 5 mg
  454. Norethisterone enantate General information
    Section
    Injectable hormonal contraceptives
    • Parenteral > General injections > IM: 200 mg per mL in 1 mL ampoule oily solution
  455. Normal immunoglobulin General information
    Section
    Human immunoglobulins
    • Parenteral > General injections > IV: 5% protein solution; 10% protein solution
    • Parenteral > General injections > IM: 16% protein solution
    • Parenteral > General injections > SC: 15% protein solution; 16% protein solution
  456. Nystatin General information
    Section
    Antifungal medicines
    • Oral > Liquid: 100000 IU per mL; 50 mg per 5 mL
    • Oral > Solid: 500000 IU tablet; 100000 IU lozenge; 100000 IU tablet
    • Local > Topical > Other: 100000 IU pessary
    Indications
  457. Ocrelizumab General information
    Section
    Immunomodulators for non-malignant disease
    • Parenteral > General injections > IV: 30 mg per mL in 10 mL vial
  458. Ofloxacin General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 200 mg; 400 mg
    Section
    Ear, nose and throat medicines [c]
    Indications
    Section
    Ophthalmological preparations > Anti-infective agents
    • Local > Ophthalmological > Solution (eye drops): 0.3%
  459. Omadacycline General information
    Section
    Reserve group antibiotics
    • Parenteral > General injections > IV: 100 mg lyophilized powder for injection
    • Oral > Solid: 300 mg
  460. Ombitasvir + paritaprevir + ritonavir General information
    Section
    Medicines for hepatitis C > Non-pangenotypic direct-acting antiviral combinations
    • Oral > Solid: 12.5 mg + 75 mg + 50 mg tablet
  461. Omeprazole General information
    Section
    Antiulcer medicines
    • Oral > Liquid: 20 mg powder for oral liquid; 40 mg powder for oral liquid
    • Oral > Solid: 10 mg; 20 mg; 40 mg
    • Parenteral > General injections > IV: 40 mg in vial
  462. Ondansetron General information
    Section
    Medicines for other common symptoms in palliative care
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base)
    Indications
    Section
    Antiemetic medicines
    • Parenteral > General injections > IV: 2 mg per mL in 2 mL ampoule (ondansetron base, as hydrochloride)
    • Oral > Liquid: 4 mg per 5 mL (ondansetron base)
    • Oral > Solid: 4 mg (ondansetron base); 8 mg (ondansetron base); 24 mg (ondansetron base)
  463. Oral rehydration salts General information
    Section
    Oral rehydration
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
    Indications
    Section
    Solutions correcting water, electrolyte and acid-base disturbances > Oral
    • Powder for dilution in 200 mL, 500 mL, 1 L:
    • - glucose 75 mEq
    • - sodium 75 mEq or mmol/L
    • - chloride 65 mEq or mmol/L
    • - potassium 20 mEq or mmol/L
    • - citrate 10 mmol/L
    • - osmolarity 245 mOsm/L
    • - glucose 13.5 g/L
    • - sodium chloride 2.6 g/L
    • - potassium chloride 1.5 g/L
    • - trisodium citrate dihydrate 2.9 g/L
  464. Oral rehydration salts - zinc sulfate General information
    Section
    Medicines used in diarrhoea
    • Oral > Other: ORS powder for dilution and zinc sulfate solid oral dosage form 20 mg (co-packaged)
    Indications
  465. Oseltamivir General information
    Section
    Other antivirals
    • Oral > Solid: 30 mg capsule (as phosphate); 45 mg capsule (as phosphate); 75 mg capsule (as phosphate)
  466. Osimertinib General information
    Section
    Targeted therapies
    • Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)
  467. Oxaliplatin General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial
  468. Oxamniquine General information
    Section
    Antischistosomals and other antitrematode medicines
    • Oral > Liquid: 250 mg per 5 mL
    • Oral > Solid: 250 mg capsule
  469. Oxazolindinones General information
    Section
    Reserve group antibiotics
    • .
  470. Oxycodone General information
    Section
    Opioid analgesics
    Indications
    Therapeutic equivalent to morphine for Pain
  471. Oxygen General information
    Section
    General anaesthetics and oxygen > Inhalational medicines
    • Respiratory > Inhalation: (medical gas)
    Section
    Medical gases
    • Respiratory > Inhalation:
  472. Oxytetracycline General information
    Section
    Ophthalmological preparations > Anti-infective agents
    Indications
    Therapeutic equivalent to tetracycline for Other specified conjunctivitis Therapeutic equivalent to tetracycline for Infectious keratitis Therapeutic equivalent to tetracycline for Infectious blepharitis Therapeutic equivalent to tetracycline for Trachoma
  473. Oxytocin General information
    Section
    Uterotonics
    • Parenteral > General injections > unspecified: 10 IU per mL
  474. P-aminosalicylic acid General information
    Section
    Antituberculosis medicines
    • Oral > Solid: 4 g granules in sachet
  475. Palbociclib General information
    Section
    Targeted therapies
    • Oral > Solid: 75 mg; 100 mg; 125 mg
  476. Paliperidone General information
    Section
    Medicines used in psychotic disorders
    • Parenteral > General injections > IM: 25 mg in pre-filled syringe (as palmitate); 50 mg in pre-filled syringe (as palmitate); 75 mg in pre-filled syringe (as palmitate); 100 mg in pre-filled syringe (as palmitate); 150 mg in pre-filled syringe (as palmitate)
  477. Palonosetron General information
    Section
    Medicines for other common symptoms in palliative care
    Indications
    Therapeutic equivalent to ondansetron for Palliative care
    Section
    Antiemetic medicines
    Indications
    Therapeutic equivalent to ondansetron for Nausea or vomiting
  478. Pancreatic enzymes General information
    Section
    Pancreatic enzymes
    • Oral > Solid: Age-appropriate formulations and doses including lipase, protease and amylase.
  479. Paracetamol General information
    Section
    Antimigraine medicines > For treatment of acute attack
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
    • Oral > Solid: 300 to 500 mg
    Indications
    Section
    Non-opioids and non-steroidal anti-inflammatory medicines (NSAIMs)
    • Oral > Liquid: 125 mg per 5 mL; 120 mg per 5 mL
    • Oral > Solid: 100 to 500 mg
    • Local > Rectal > Suppository: 100 mg
    Indications
  480. Paromomycin General information
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 750 mg paromomycin base (as sulfate)
    Section
    Antiamoebic and antigiardiasis medicines
    • Oral > Liquid: 125 mg per 5 mL as sulfate
    • Oral > Solid: 250 mg as sulfate
    Indications
  481. Paroxetine General information
    Section
    Medicines used in depressive disorders
    Indications
    Therapeutic equivalent to fluoxetine for Depressive disorders
  482. Pegaspargase General information
    Section
    Cytotoxic medicines
    • Parenteral > General injections > IV: 3750 units per 5 mL in vial
  483. Pegylated interferon alfa (2a) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 180 µg in vial; 180 µg in prefilled syringe
  484. Pegylated interferon alfa (2b) General information
    Section
    Medicines for hepatitis C > Other antivirals for hepatitis C
    • Parenteral > General injections > SC: 80 µg in prefilled syringe; 100 µg in prefilled syringe
  485. Pembrolizumab General information
    Section
    Immunomodulators
    • Parenteral > General injections > IV: 50 mg powder for injection
  486. Penicillamine General information
    Section
    Antidotes and other substances used in poisonings > Specific
    • Oral > Solid: 250 mg
    Section
    Disease-modifying anti-rheumatic drugs (DMARDs)
    • Oral > Solid: 250 mg
  487. Pentamidine General information
    Section
    Medicines for the treatment of 1st stage African trypanosomiasis
    • Parenteral > General injections > IM: 200 mg (as isetionate) powder for injection
    Section
    Antileishmaniasis medicines
    • Parenteral > General injections > IM: 200 mg (as isetionate); 300 mg (as isetionate)
    Section
    Antipneumocystosis and antitoxoplasmosis medicines
    • Oral > Solid: 200 mg tablet; 300 mg tablet
    Indications
  488. Permethrin General information
    Section
    Dermatological medicines (topical) > Scabicides and pediculicides
    • Local > Topical > Lotion: 1%
    • Local > Topical > Cream: 5%
  489. Pertussis vaccine General information
    Section
    Recommendations for all immunization programmes
    • All vaccines should comply with the WHO requirements for biological substances.
  490. Pertuzumab General information
    Section
    Targeted therapies
    • Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution
  491. Phenobarbital General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 15 mg per 5 mL
    • Oral > Solid: 15 to 100 mg
    • Parenteral > General injections > IV: 200 mg per mL in ampoule (phenobarbital sodium)
  492. Phenoxymethylpenicillin General information
    Section
    Access group antibiotics
    • Oral > Liquid: 250 mg per 5 mL (as potassium salt) powder for oral liquid
    • Oral > Solid: 250 mg (as potassium salt) tablet
    • Oral > Solid: 250 mg (as potassium salt); 500 mg (as potassium salt)
  493. Phenytoin General information
    Section
    Anticonvulsants/antiepileptics
    • Oral > Liquid: 25 to 30 mg per 5 mL
    • Oral > Solid: 25 mg (sodium salt); 100 mg (sodium salt); 50 mg (sodium salt); 50 mg chewable tablet
    • Parenteral > General injections > unspecified: 50 mg per mL in 5 vial (sodium salt)
  494. Phytomenadione General information
    Section
    Medicines affecting coagulation
    • Parenteral > General injections > IV: 10 mg per mL in ampoule; 1 mg per mL in ampoule
    • Oral > Solid: 10 mg tablet
  495. Pilocarpine General information
    Section
    Ophthalmological preparations > Miotics and antiglaucoma medicines
    • Local > Ophthalmological > Solution (eye drops): 2% (hydrochloride or nitrate); 4% (hydrochloride or nitrate)
  496. Piperacillin + tazobactam General information
    Section
    Watch group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Section
    Access group antibiotics
    • Parenteral > General injections > IV: 2 g (as sodium salt) + 250 mg (as sodium salt) powder for injection; 4 g (as sodium salt) + 500 mg (as sodium salt) powder for injection
    Indications
    First choice
    co-prescribed with clindamycin Necrotising fasciitis
  497. Platelets General information
    Section
    Blood and blood components
    • Parenteral > General injections > IV:
  498. Plazomicin General information
    Section